This is a live streamed only, three day professional conference on advances in cellular therapy. We have gathered together invited speakers from around the world, who you might not otherwise have access to.
Bringing together scientists, clinicians and pharma together to discuss developments and challenges in the translation of cell-based therapies.
Event Description: With major advances in cell and molecular biology, the potential of cellular therapies is now beginning to be realised. Stem cell and T cell-based products are being developed for the treatment of a wide range of therapeutic applications, including cancer, autoimmunity, and degenerative diseases. In many cases, they can offer a novel means of treating previously unmet medical needs. Sophisticated bioengineering techniques are increasingly being incorporated into the production of cellular therapies, such as CAR-T cells, extending their therapeutic range. However, as treatments move from the laboratory into the clinic, it is essential that robust, reliable and economically viable scaling and manufacturing processes are developed for the commercialisation of cell-based therapies. This event will provide an opportunity to for those involved at all stages of the product life cycle to discuss recent successes and continuing challenges in the development, manufacture and clinical application of cell therapies.
We encourage questions, discussion and debate and have a relaxed atmosphere which generates maximum interaction online.
After registration you will be connected to an online networking site where you will be able to have discussions with all participants of this event, before, during and after the meeting.
Who Should Attend: Research scientists, clinicians and pharmaceutical professionals involved in basic and translational research related to the development, manufacture and clinical application of cell-based therapies.
Oral Abstract Submission Deadline: 10th June 2017
Early Registration Deadline: 20th July 2017
Poster Submissions Deadline: 29th August 2017
Invited speakers and their talks include:
|Ex vivo Gene Editing: A Regulatory Pathway for Clinical Implementation||Dr. Houria Bachtarzi||ERA Consulting (UK) Ltd., London, United Kingdom||United Kingdom|
|TBC||Hassan Abd-Allah, Somia||Zagazig University ||Egypt|
|Assessing and Resolving the “Last Mile” Challenge in Cell Therapy||Mr Samuel Kent||Chief Commercial Officer |
|Evaluation of factors that influence T regulatory cell content in allogeneic stem cell transplants||Dr Abigail Lamikanra||Blood Research Laboratory|
John Radcliffe Hospital
|TBC||Ohad Karnieli,||Karnieli Ltd||United States|
|Tolerogenic dendritic cell therapy for rheumatoid arthritis||Dr. Catharien Hilkens||Newcastle University|
Institute of Cellular Medicine
|TBC||Ana V Villar,||University of Cantabria||Spain|
|TBC||Professor John D Isaacs||Newcastle University||United Kingdom|
Advances in Cellular Therapy has an open abstract session.
Abstracts can be submitted on any subject related to Cellular Therapy.
A Euroscicon live streamed event gives you access to a wider range of international speakers at a fraction of the cost of a real world event. Furthermore, you no longer have to worry about travel or accommodation expenses, or any arrangements you have which clash with our events.
Advisory Board Members
|Mr. Omar El-Shaarawy||Menoufia University||Egypt|